Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity

被引：1
|
作者：
Della-Morte, David [1 ,2 ]
Riondino, Silvia [1 ,2 ]
Ferroni, Patrizia [2 ]
Palmirotta, Raffaele [2 ]
Pastore, Donatella [1 ]
Lauro, Davide [1 ]
Guadagni, Fiorella [2 ]
Roselli, Mario [1 ]
机构：
[1] Univ Roma Tor Vergata, Dept Syst Med, Sch Med, I-00133 Rome, Italy
[2] IRCCS San Raffaele Pisana Res Ctr, Biomarker Discovery & Adv Technol BioDAT Lab, Rome, Italy
来源：
PHARMACOGENOMICS | 2015年 / 16卷 / 01期
关键词：
angiogenesis; cancer; elderly; genetics; single nucleotide polymorphisms; tumor prognosis; vascular endothelial growth factors; VEGF; VEGF inhibitors; ENDOTHELIAL-GROWTH-FACTOR; RENAL-CELL CARCINOMA; METASTATIC COLORECTAL-CANCER; SINGLE NUCLEOTIDE POLYMORPHISMS; GENDER-SPECIFIC ASSOCIATION; BEVACIZUMAB-BASED THERAPY; ADVANCED BREAST-CANCER; LUNG-CANCER; PROSTATE-CANCER; TUMOR ANGIOGENESIS;
D O I：
10.2217/PGS.14.136
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Vascular endothelial growth factors (VEGFs) are the key regulators in angiogenesis and have been shown to play a significant role in the progression and prognosis of angiogenesis-related diseases, such as cancer. VEGF inhibitors are a current pharmacological antitumoral strategy. However, despite the strong association between aging and cancer incidence and progression, recent findings suggest impaired angiogenesis accompanied by a reduced expression of VEGF in cells derived from aging subjects. Specific variations of VEGF genes have been demonstrated to be genetic determinants for susceptibility, outcome and therapy response, especially for the solid tumors. Considering the complications present in frail elderly patients, analysis of VEGF genetic polymorphisms in these subjects may further help in tailoring an antiangiogenic pharmacological strategy, and in improving our ability to better understand prognosis during therapy-related to cancer.
引用
收藏
页码：61 / 78
页数：18
相关论文
共 50 条
  • [1] Impact of VEGF Gene Polymorphisms and Haplotypes on Radiation-Induced Late Toxicity in Prostate Cancer Patients
    Langsenlehner, Tanja
    Renner, Wilfried
    Gerger, Armin
    Hofmann, Guenter
    Thurner, Eva-Maria
    Kapp, Karin S.
    Langsenlehner, Uwe
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (12) : 784 - 791
  • [2] VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients
    Camerin, Gabriela Ribeiro
    Carvalho Brito, Angelo Borsarelli
    Vassallo, Jose
    Mauricette Derchain, Sophie Francoise
    Passos Lima, Carmen Silvia
    FUTURE ONCOLOGY, 2017, 13 (05) : 409 - 414
  • [3] Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
    Berardi, Rossana
    Brunelli, Alessandro
    Pagliaretta, Silvia
    Paolucci, Vittorio
    Conti, Alessandro
    Goteri, Gaia
    Refai, Majed
    Pompili, Cecilia
    Marcantognini, Giulia
    Morgese, Francesca
    Ballatore, Zelmira
    Savini, Agnese
    De Lisa, Mariagrazia
    Caramanti, Miriam
    Santoni, Matteo
    Zizzi, Antonio
    Piva, Francesco
    Mazzanti, Paola
    Onofri, Azzurra
    Sabbatini, Armando
    Scarpelli, Marina
    Cascinu, Stefano
    ONCOTARGET, 2015, 6 (22) : 19305 - 19315
  • [4] VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients
    Ferroni, Patrizia
    Palmirotta, Raffaele
    Riondino, Silvia
    De Marchis, Maria Laura
    Nardecchia, Antonella
    Formica, Vincenzo
    Guadagni, Fiorella
    Roselli, Mario
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (01) : 143 - 151
  • [5] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    Scartozzi, M.
    Bianconi, M.
    Faloppi, L.
    Loretelli, C.
    Bittoni, A.
    Del Prete, M.
    Giampieri, R.
    Maccaroni, E.
    Nicoletti, S.
    Burattini, L.
    Minardi, D.
    Muzzonigro, G.
    Montironi, R.
    Cascinu, S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1126 - 1132
  • [6] Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
    Lemos, Clara
    Giovannetti, Elisa
    Zucali, Paolo A.
    Assaraf, Yehuda G.
    Scheffer, George L.
    van der Straaten, Tahar
    D'Incecco, Armida
    Falcone, Alfredo
    Guchelaar, Henk-Jan
    Danesi, Romano
    Santoro, Armando
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    Peters, Godefridus J.
    PHARMACOGENOMICS, 2011, 12 (02) : 159 - 170
  • [7] Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer
    Chen, N.
    Ma, C. N.
    Zhao, M.
    Zhang, Y. J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 16006 - 16011
  • [8] VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population
    Maltese, Paolo
    Canestrari, Emanuele
    Ruzzo, Annamaria
    Graziano, Francesco
    Falcone, Alfredo
    Loupakis, Fotios
    Tonini, Giuseppe
    Santini, Daniele
    Magnani, Mauro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (02) : 165 - 170
  • [9] Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer
    Xie, Shuang
    Zhou, Feng
    Wang, Jiaojiao
    Cao, Haiyan
    Chen, Yibing
    Liu, Xiaonan
    Zhang, Zhaohui
    Dai, Jingyao
    He, Xianli
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [10] The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
    Oh, Sung Yong
    Kwon, Hyuk-Chan
    Kim, Sung Hyun
    Lee, Suee
    Lee, Ji Hyun
    Hwang, Jung-Ah
    Hong, Seung Hyun
    Graves, Christian A.
    Camphausen, Kevin
    Kim, Hyo-Jin
    Lee, Yeon-Su
    BMC CANCER, 2013, 13
12345